The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)
RJ Knox, F Friedlos, MP Boland - Cancer and Metastasis Reviews, 1993 - Springer
Walker cellsin vivo orin vitro are exceptionally sensitive to the monofunctional alkylating
agent CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). The basis of the sensitivity is that CB …
agent CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). The basis of the sensitivity is that CB …
Mechanism of Cytotoxicity of Anticancer Platinum Drugs: Evidence That cis-Diamminedichloroplatinum(II) and cis-Diammine-(1,1-cyclobutanedicarboxylato)platinum …
RJ Knox, F Friedlos, DA Lydall, JJ Roberts - Cancer research, 1986 - AACR
… and Friedlos, F. DNA repair characteristics of Walker rat carcinoma cells sensitive and
resistant to cis-diamminedichlo roplatinum(II)(cisplatin)and difunctionalalkylatingagents. In: KR …
resistant to cis-diamminedichlo roplatinum(II)(cisplatin)and difunctionalalkylatingagents. In: KR …
B-RAF is a therapeutic target in melanoma
…, R Hayward, D Niculescu-Duvaz, I Scanlon, F Friedlos… - Oncogene, 2004 - nature.com
B-RAF is a serine/threonine-specific protein kinase that is mutated in approximately 70% of
human melanomas. However, the role of this signalling molecule in cancer is unclear. Here, …
human melanomas. However, the role of this signalling molecule in cancer is unclear. Here, …
The bioactivation of 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB1954)—I: purification and properties of a nitroreductase enzyme from Escherichia coli—a potential …
…, RG Melton, RF Sherwood, B Coles, F Friedlos… - Biochemical …, 1992 - Elsevier
A nitroreductase enzyme has been isolated from Escherichia coli B. This enzyme is an FMN-containing
flavoprotein with a molecular mass of 24 kDa and requires either NADH or …
flavoprotein with a molecular mass of 24 kDa and requires either NADH or …
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin
S da Rocha Dias, F Friedlos, Y Light, C Springer… - Cancer research, 2005 - AACR
Hsp90 is a ubiquitously expressed molecular chaperone that folds, stabilizes, and
functionally regulates many cellular proteins. The benzoquinone ansamysin 17-allylamino-17-…
functionally regulates many cellular proteins. The benzoquinone ansamysin 17-allylamino-17-…
Quantitative estimation of cisplatin-induced DNA interstrand cross-links and their repair in mammalian cells: relationship to toxicity
JJ Roberts, F Friedlos - Pharmacology & therapeutics, 1987 - Elsevier
… ld-f) wherein it is seen that increasing doses of cisplatin produce a progressive increase in
molecular weight, as would be expected were cross-linking occurring. It has been calculated …
molecular weight, as would be expected were cross-linking occurring. It has been calculated …
A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB …
RJ Knox, F Friedlos, M Jarman, JJ Roberts - Biochemical pharmacology, 1988 - Elsevier
… Roberts JJ, Friedlos F and Knox RJ, CB 1954 (2,4dinitro-5-aziridinyl benzamide) becomes
a DNA interstrand crosslinking agent in Walker tumour cells. Biothem Biophys Res Commun …
a DNA interstrand crosslinking agent in Walker tumour cells. Biothem Biophys Res Commun …
The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a …
RJ Knox, MP Boland, F Friedlos, B Coles… - Biochemical …, 1988 - Elsevier
… , Biock F, Institute of Cancer Research, CotswoId Rd., Sutton, Surrey, SM2 SNG, UK … Roberts
JJ, Friedlos F and Knox RJ, CB 1954 (2,4- … Knox RJ: Friedlos F, Jarman M and Roberts JJ, A …
JJ, Friedlos F and Knox RJ, CB 1954 (2,4- … Knox RJ: Friedlos F, Jarman M and Roberts JJ, A …
Attenuated Salmonella Targets Prodrug Activating Enzyme Carboxypeptidase G2 to Mouse Melanoma and Human Breast and Colon Carcinomas for Effective …
F Friedlos, P Lehouritis, L Ogilvie, D Hedley… - Clinical Cancer …, 2008 - AACR
Purpose: We engineered the oncolytic Salmonella typhimurium–derived bacterium
VNP20009 as a vector to target delivery to tumors of the prodrug-activating enzyme …
VNP20009 as a vector to target delivery to tumors of the prodrug-activating enzyme …
Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme
…, PJ Burke, HH Somani, F Friedlos… - Journal of Medicinal …, 1994 - ACS Publications
The synthesis and properties of some prodrug candidates for antibody-directed enzyme
prodrug therapy (ADEPT) are described. These compounds have been designed to generate …
prodrug therapy (ADEPT) are described. These compounds have been designed to generate …